Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$17.45
-0.30 (-1.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-14.8M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.4B
P/E
343.0x
↑EV/EBITDA
144.7x
↑ROE
-0.7%
↓Gross Margin
79.6%
↑Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-12.6%
FCF CAGR
—
FCF margin
-1.5%
FCF / Net income
0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $998.1M · net income $-25.0M · FCF $-14.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $998.1M | $998.1M | $1.09B | $927.1M | $1.49B |
| Net Income | $-25.0M | $-25.0M | $325.4M | $139.8M | $249.0M |
| EBITDA | $36.9M | $36.9M | $441.9M | $202.7M | $292.7M |
| EPS | -0.06 | -0.06 | 0.77 | 0.33 | 0.59 |
| Gross Margin | 79.6% | 79.6% | 83.4% | 85.9% | 88.2% |
| Operating Margin | 6.0% | 6.0% | 7.9% | 5.2% | 10.4% |
| Net Margin | -2.5% | -2.5% | 29.7% | 15.1% | 16.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.16 | 0.16 | 0.15 | 0.11 | 0.01 |
| Current Ratio | 2.61 | 2.61 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-14.8M | $-14.8M | $114.8M | $-229.8M | $-267.6M |
| Returns | |||||
| ROE | -0.7% | -0.7% | 8.2% | 3.7% | 6.7% |
| Valuation | |||||
| P/E | 343.00 | 343.00 | 18.69 | 44.88 | 26.98 |
| EV/EBITDA | 144.66 | 144.66 | 9.81 | 24.28 | 19.02 |
| P/B | 1.90 | 1.90 | 1.53 | 1.66 | 1.81 |
| Growth & Yield | |||||
| Revenue Growth | -8.8% | -8.8% | 18.0% | -37.9% | — |
| EPS Growth | -107.8% | -107.8% | 133.3% | -44.1% | — |
| Dividend Yield | 2.7% | 2.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+26.4%
Start / end P/E
n/dx → n/dx
EPS bridge
0.77 → -0.06
Residual
+23.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.